Sanofi has stepped up its expectations for the entire year, following a strong second quarter. In recent months, the French pharmaceutical industry has experienced double-digit growth in vaccine and rare disease activities. The company is now counting on a 5 percent increase in earnings per share, which previously assumed 3 to 5 percent more profit. CEO Olivier Brandicourt states that the performance in the past quarter was solid, which is why he has confidence in the outlook for the rest of the year. Sanofi has written off a write-off of 1.8 billion euros for the haemophilia Eloctate remedy, following lower sales in the United States and downward adjustment of sales forecasts. Eloctate was developed by the American Bioverativ. Sanofi bought that company last year for $ 11.6 billion. Adjusted for the aforementioned charge and for exchange rate effects, the quarterly profit increased by 4.9 percent compared to a year earlier, to 1.6 billion euros. The quarterly revenues increased by 3.9 percent to 8.6 billion euros.